These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1461 related articles for article (PubMed ID: 30779077)
21. MicroRNA-25-3p promotes cisplatin resistance in Non-small-cell lung carcinoma (NSCLC) through adjusting PTEN/PI3K/AKT route. Sun B; Hu N; Cong D; Chen K; Li J Bioengineered; 2021 Dec; 12(1):3219-3228. PubMed ID: 34266345 [TBL] [Abstract][Full Text] [Related]
22. [Study on the Role and Mechanism of METTL3 Mediating the Up-regulation of m6A Modified Long Non-coding RNA THAP7-AS1 in Promoting the Occurrence of Lung Cancer]. Zhang Y; Wang Y; Liu M Zhongguo Fei Ai Za Zhi; 2024 Jan; 26(12):919-933. PubMed ID: 38163978 [TBL] [Abstract][Full Text] [Related]
23. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis. Wang L; Shang X; Feng Q Cancer Biol Ther; 2019; 20(3):261-271. PubMed ID: 30481109 [TBL] [Abstract][Full Text] [Related]
24. ROR1-AS1 knockdown inhibits growth and invasion and promotes apoptosis in NSCLC cells by suppression of the PI3K/Akt/mTOR pathway. Li F; Gu F; Li Q; Zhai C; Gong R; Zhu X J Biochem Mol Toxicol; 2021 May; 35(5):e22726. PubMed ID: 33491326 [TBL] [Abstract][Full Text] [Related]
25. MiR-4299 suppresses non-small cell lung cancer cell proliferation, migration and invasion through modulating PTEN/AKT/PI3K pathway. Yang WB; Zhang WP; Shi JL; Wang JW Eur Rev Med Pharmacol Sci; 2018 Jun; 22(11):3408-3414. PubMed ID: 29917192 [TBL] [Abstract][Full Text] [Related]
26. Effects of long non-coding RNA (lncRNA) cancer susceptibility candidate 2c (CASC2c) on proliferation, metastasis and drug resistance of non-small cell lung cancer (NSCLC) cells through ERK1/2 and β-catenin signaling pathways. Tong L; Wu W Pathol Res Pract; 2019 Sep; 215(9):152522. PubMed ID: 31300295 [TBL] [Abstract][Full Text] [Related]
27. Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway. Ma LY; Xie XW; Ma L; Pang JL; Xiong XM; Zheng HD; Shen XL; Wen ZG; Wang HY Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2626-2634. PubMed ID: 28678322 [TBL] [Abstract][Full Text] [Related]
28. Long non-coding RNA SNHG15 indicates poor prognosis of non-small cell lung cancer and promotes cell proliferation and invasion. Dong YZ; Meng XM; Li GS Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2671-2679. PubMed ID: 29771418 [TBL] [Abstract][Full Text] [Related]
29. Knockdown of lncRNA GHET1 suppresses cell proliferation, invasion and LATS1/YAP pathway in non small cell lung cancer. Guan ZB; Cao YS; Li Y; Tong WN; Zhuo AS Cancer Biomark; 2018 Feb; 21(3):557-563. PubMed ID: 29286919 [TBL] [Abstract][Full Text] [Related]
30. LINC01093 promotes proliferation and invasion of non-small cell lung cancer cells via targeting akt signaling pathway. Wang ZX; Xu ZN; Sun HB; Wang Y; Han ZF; Yu Y; Han XL; Yin YY; Xu L Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):222-229. PubMed ID: 31957835 [TBL] [Abstract][Full Text] [Related]
31. Long non‑coding RNA TP73‑AS1 accelerates the progression and cisplatin resistance of non‑small cell lung cancer by upregulating the expression of TRIM29 via competitively targeting microRNA‑34a‑5p. Luo S; Shen M; Chen H; Li W; Chen C Mol Med Rep; 2020 Nov; 22(5):3822-3832. PubMed ID: 32901838 [TBL] [Abstract][Full Text] [Related]
32. Exosomal lncRNA FOXD3-AS1 upregulates ELAVL1 expression and activates PI3K/Akt pathway to enhance lung cancer cell proliferation, invasion, and 5-fluorouracil resistance. Mao G; Mu Z; Wu DA Acta Biochim Biophys Sin (Shanghai); 2021 Nov; 53(11):1484-1494. PubMed ID: 34605863 [TBL] [Abstract][Full Text] [Related]
33. Activation of PI3K/Akt pathway by G protein-coupled receptor 37 promotes resistance to cisplatin-induced apoptosis in non-small cell lung cancer. Liu H; Zhu Y; Niu H; Jie J; Hua S; Bai X; Wang S; Song L Cancer Med; 2023 Oct; 12(19):19777-19793. PubMed ID: 37732632 [TBL] [Abstract][Full Text] [Related]
34. LncRNA TRERNA1 promotes malignant progression of NSCLC through targeting FOXL1. Luo DB; Lv HB; Sun XH; Wang Y; Chu JH; Salai AL Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1233-1242. PubMed ID: 32096153 [TBL] [Abstract][Full Text] [Related]
35. LncRNA AB073614 regulates proliferation and metastasis of colorectal cancer cells via the PI3K/AKT signaling pathway. Wang Y; Kuang H; Xue J; Liao L; Yin F; Zhou X Biomed Pharmacother; 2017 Sep; 93():1230-1237. PubMed ID: 28738539 [TBL] [Abstract][Full Text] [Related]
36. LncRNA SNHG12 Decreases Non-Small Cell Lung Cancer Cell Sensitivity to Cisplatin by Repressing miR-525-5p and Promoting XIAP. Tan D; Wang S; Zhang P; Peng C; Wu T Ann Clin Lab Sci; 2023 Jan; 53(1):64-75. PubMed ID: 36889771 [TBL] [Abstract][Full Text] [Related]
37. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a. Cheng C; Qin Y; Zhi Q; Wang J; Qin C Int J Biol Macromol; 2018 Feb; 107(Pt B):2620-2629. PubMed ID: 29080815 [TBL] [Abstract][Full Text] [Related]
38. Long non-coding RNA LINP1 functions as an oncogene in endometrial cancer progression by regulating the PI3K/AKT signaling pathway. Zhang XH; Li M; Kang YJ; Xie YQ; Cao YX Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6830-6838. PubMed ID: 31486482 [TBL] [Abstract][Full Text] [Related]
39. Downregulation of long non-coding RNA DBH-AS1 inhibits osteosarcoma progression by PI3K-AKT signaling pathways and indicates good prognosis. Liu ZB; Wang JA; Lv RQ Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1418-1427. PubMed ID: 30840262 [TBL] [Abstract][Full Text] [Related]
40. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression. Xia A; Li H; Li R; Lu L; Wu X Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]